How glycaemic index affects blood sugar and discover practical guidance on low-GI foods, meal choices and healthier eating for diabetes management.
Research from Australia indicates that common diabetes drugs called GLP-1 receptor agonists could improve lung capacity and metabolic outcomes in adults with cystic fibrosis-related diabetes, though larger studies are needed. GLP-1 receptor agonist medicines, which are already widely used for…
A Danish study reveals that unemployed and retired adults with type 2 diabetes and cardiovascular disease are less likely to receive recommended glucose-lowering treatments, highlighting ongoing disparities in healthcare access. A large Danish registry study has found that adults with…
A new study reveals that triglyceride–glucose indices and waist-to-height ratio may identify seniors at risk of cognitive deterioration by detecting subtle white matter changes, highlighting a potential biological pathway from insulin resistance to brain ageing. The triglyceride–glucose index and a…
Experts affirm that whole fruit remains a nutritious, weight-friendly, and blood sugar-conscious part of a balanced diet, provided portion sizes and overall carbohydrate intake are considered. Advances clarify misconceptions about fruit’s impact on health, emphasising the importance of form and…
A new indirect analysis suggests that Lilly’s oral GLP-1 pill Foundayo could offer marginally better weight loss and blood sugar control than the highest tested dose of oral semaglutide, raising questions about competitive advantages ahead of direct comparison trials. Eli…
DreaMed Diabetes has gained FDA approval for MODI, a prescription app that uses CGM data to autonomously recommend insulin adjustments for adults with type 2 diabetes on injections, extending automation beyond pump users and potentially transforming insulin care. DreaMed Diabetes…
Eli Lilly’s orforglipron claims a slight advantage over higher-dose oral semaglutide in weight loss and blood sugar reduction, signalling intensified competition in the race to develop effective oral GLP-1 therapies. Eli Lilly says its oral diabetes pill orforglipron has shown…
Eli Lilly’s initiative to deliver Mounjaro directly to patients’ homes prompts criticism from Australian doctors and pharmacists concerned over reduced clinical oversight and safety risks amid growing use of GLP-1 medications for diabetes and obesity. Eli Lilly’s plan to sell…
A new analysis presented at the European Association for the Study of Diabetes suggests that increasing the dose of semaglutide to 2 mg may offer better cardiovascular protection for adults with type 2 diabetes compared to switching to tirzepatide, raising…
New guidelines and recent trials position SGLT2 inhibitors such as dapagliflozin, empagliflozin, and canagliflozin as crucial for slowing chronic kidney disease progression, including in patients without diabetes, with safety considerations and lifestyle factors emphasised. SGLT2 inhibitors have moved from being…
Huawei claims it is close to launching a consumer device capable of measuring blood sugar non-invasively, marking a potential breakthrough in health tracking technology after years of research and patent filings suggesting multiple innovative approaches. Huawei says it is edging…
A comprehensive review presented at the European Association for the Study of Diabetes indicates that GLP-1 drugs do not significantly increase adverse pregnancy outcomes, though calls for more definitive evidence persist. New research to be presented at the European Association…
